share_log

神州细胞(688520.SH):SCT-I10A单抗已有肝癌和头颈癌两个适应症正在上市审评阶段

Shenzhou Cell (688520.SH): The SCT-I10A monoclonal antibody has two indications for liver cancer and head and neck cancer in the market approval stage.

Gelonghui Finance ·  Nov 14, 2024 23:59

Gelonghui November 15th 丨 Investor Relations Activity Record of Shenzhou Cell (688520.SH) shows that SCT-I10A monoclonal antibody has two indications for liver cancer and head and neck cancer in the market approval stage, with no other indications currently planned for market approval.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment